Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Recruiting · NCT07398417 · Registry updated 2026-09-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | Hyperalgesia, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Somatosensory Disorders, fibromyalgia, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, rheumatic disorder | Recruiting | Phase 3 | 2026-09-04 | NCT07398417 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Axsome Therapeutics, Inc. | 14 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Houston | High Point | United States | 1 |